Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum + Bifidobacterium to protect intestinal flora during azithromycin + cefamandole therapy
ChiCTR-TRC-13004924Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jul 2014
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of clostridium butyricum and Golden Bifid in bronchopneumonia, Mycoplasmal pneumonia and bacterial pneumonia (4 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Fecal flora composition and abundance analysis, Fecal flora metabolic index and 2 more. Started Jul 2014; status: recruiting.
02
Drugs
clostridium butyricumGolden Bifid
03
Conditions
bronchopneumoniaMycoplasmal pneumoniabacterial pneumonia
Beyond the preview
Go deeper on ChiCTR-TRC-13004924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004924.